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Background: Spirometry-based parameters of pulmonary function such as forced expiratory volume in 1 second
(FEV1) have prognostic value beyond respiratory morbidity and mortality. FEV1 divided by height cubed (FEV1/Ht
3)
has been found to be better at predicting all-cause mortality than the usual standardization as percentage of predicted
"normal values" (FEV1%) and its use is independent of reference equations. Yet, limited data are available on the very
old adults (80 years and older) and in association to other adverse health outcomes relevant for this age group. This
study aims to investigate the short-term prognostic value of FEV1/Ht
3 for all-cause mortality, hospitalization, physical
and mental decline in a cohort of very old adults.
Methods: In a population-based prospective cohort study of 501 very old adults in Belgium, comprehensive geriatric
assessment and spirometry were performed at baseline and after 1.7 ± 0.21 years. Kaplan-Meier curves for 3-year all-cause
mortality and hospitalization rates and multivariable analysis adjusted for age, sex, smoking status, co-morbidities, anemia,
high C reactive protein and creatinine levels examined the association of FEV1/Ht
3 with all-cause mortality, unplanned
hospitalization and decline in mental and physical functioning. Physical functioning was assessed by activities of
daily living, a battery of physical performance tests and grip strength. Mental functioning was assessed with mini
mental state examination and 15 items geriatric depression scale.
Results: Individuals in the lowest quartile of FEV1/Ht
3 had a statistically significant increased adjusted risk for all-cause
mortality (hazard ratio [HR] 1.69, 95% confidence interval [CI] 1.10-2.60) and unplanned hospitalization (HR 1.65, 95% CI
1.21-2.25), as well as decline in physical (odds ratio [OR] 1.89, 95% CI 1.05-3.39) and mental functioning (OR 2.39, 95% CI
1.30-4.40) compared to the rest of the study population.
Conclusions: In a cohort of very old adults, low FEV1 expressed as FEV1/Ht
3 was found to be a short-term predictor of
all-cause mortality, hospitalization and decline in physical and mental functioning independently of age, smoking
status, chronic lung disease and other co-morbidities. Further research is needed on FEV1/Ht
3 as a potential risk
marker for frailty and adverse health outcomes in this age group.Background
The prognostic value of the spirometry parameters of
pulmonary function (PF) such as forced expiratory vol-
ume in 1 second (FEV1) and forced vital capacity (FVC)
has been found to extend beyond respiratory morbidity
and mortality into overall morbidity, mortality and other* Correspondence: eralda.turkeshi@student.uclouvain.be
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unless otherwise stated.adverse health outcomes [1-5]. Inflammatory markers seem
to have a significant role in the multiple pathways that link
PF to overall mortality and morbidity [4,6]. Impaired PF
has also been found to be associated with reduced physical
performance and disability in community-dwelling adults
[7-10], while lower PF measures at midlife have been found
to be independently associated with lower cognitive per-
formance in later life [7,11-17]. Recently, cross-sectional
and longitudinal analysis has also shown that impaired PF
and frailty are strongly associated and both increase the
risk for mortality in older adults [18], leading to furtherl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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nostic markers of adverse health outcomes in this world-
wide growing age group.
Yet the interpretation of key spirometry parameters is
an area of ongoing discussion, especially for the older
adults [19]. The common approach of expressing FEV1
as percentage of a predicted “normal” value (FEV1%) is
dependent on reliable age-specific reference values de-
rived from spirometry data of "healthy" people of
equivalent age and gender, but these have been relatively
lacking for the very old adults until recently when the
Global Lung Initiative (GLI) all-age reference equations
have been made available for populations up to 95 years
old [20,21]. Yet, the GLI reference equations need to be
validated for people over 80 years old and more data are
needed for this age group [21]. The FEV1% approach
also does not account for the variability of predicted
values that is even higher in the older adults [20,22].
These limitations of FEV1% have lead to exploration of
alternative ways of standardizing FEV1 such as FEV1
standardized residuals (FEV1SR or z-scores), FEV1 di-
vided by height squared or cubed (FEV1/Ht
3) or as a
function of the sex-specific first percentile (FEV1 quo-
tient (FEV1Q) with the last two being found to be super-
ior to FEV1% in predicting all-cause mortality [23-27].
Studies on the ability of these alternative expressions of
FEV1 to predict mortality in the very old adults and
other relevant adverse health outcomes for this age
group are very limited.
The aim of this study is to investigate the short-term
prognostic value of FEV1/Ht
3 for all-cause mortality and
unplanned hospitalizations as well as declines in physical
and mental functioning in a cohort of very old adults.
FEV1/Ht
3 was investigated in this study as its use is in-
dependent of reference equations.
Methods
Study design and population
The BELFRAIL study (BFc80+) is a prospective, observa-
tional, population-based cohort study of people aged
80 years or older living in Belgium aiming to acquire a
better understanding of the epidemiology and patho-
physiology of chronic diseases in this age-group and to
study the dynamic interaction between health, frailty
and disability in a multi-system approach. The study
protocol and sampling methods have been already de-
scribed [28]. Briefly, between November 2008 and
September 2009, in 29 general practice centers, 567 indi-
viduals aged 80 years and older were included in the
BFc80+, excluding only those with severe dementia (de-
fined as a mini-mental state examination ≤15/30) and
those in palliative or emergency care. At baseline (T0),
the participants' general practitioners (GP) recorded
socio-demographic data and medical history. An extensiveassessment by a clinical research assistant (CRA) included
performance tests, questionnaires and technical examina-
tions such as spirometry as well as collection of blood
samples for laboratory tests. The same comprehensive as-
sessment was repeated at 1.7 ± 0.21 years from baseline
(T1). Hospitalization and mortality data were collected
periodically until 3.0 ± 0.25 years from baseline (Figure 1).
The study protocol was approved by the Biomedical Ethics
Committee of the Medical School of the Universite Catho-
lique de Louvain (UCL) in Brussels, Belgium. All partici-
pants gave written informed consent.
Baseline spirometry
All spirometry data were gathered by two trained CRAs
using a Spirobank spirometer (Medical International Re-
search, Rome, Italy) that has been previously found to be
reliable for research purposes [29]. After demonstration
of the correct spirometry maneuver, participants per-
formed up to eight forced vital capacity maneuvers or
until exhaustion to achieve the acceptability and repeat-
ability criteria of the American Thoracic Society (ATS)/
European Respiratory Society (ERS) [30]. Repeatability of
the spirometry was calculated automatically in accordance
with these criteria. Two independent researchers evalu-
ated all spirograms by the ATS/ERS criteria and classified
them in the following levels: 1 – all criteria concerning
acceptability and repeatability are fulfilled; 2 – all cri-
teria are fulfilled except duration of expiration > 6 sec-
onds; 3 –spirograms have good starts and no cough
during the 1st second of manoeuvre; 4 – none of the
criteria are fulfilled. Standardized measurements of
height were performed during the CRA visit at T0. FEV1
was expressed as FEV1 divided by height cubed and
ranked in quartiles.
All-cause mortality and hospitalizations
The detailed follow-up questionnaires received from the
GPs of the participants at 1.4 ± 0.26 years and 3.0 ±
0.25 years after the baseline (Figure 1) reported on the
date and cause of mortality and hospitalizations. All-cause
mortality and time to first unplanned hospitalization after
the CRA visit at T0 were used as outcome measurements.
Physical decline
Activities of daily living (ADL), physical performance
tests (PPT) and grip strength were used as measures of
physical functioning. Physical decline was defined as a
relevant decline in any of these tests between T0 and T1.
The ADL consisted of asking the respondents to de-
scribe the degree of difficulty they have with six activities
of daily living: climbing stairs, walking 5 minutes out-
doors without resting, getting up and sitting down in a
chair, dressing and undressing oneself, using own or
public transport and cutting one's own nails [31]. The
CRA visit at T0
Follow up questionnaire 1
Follow up questionnaire 2
CRA visit at T1
Figure 1 Flowchart of the data collection in the BELFRAIL study CRA: clinical research assistant; GP: general practitioner; ADL: activities
of daily living; PPT: physical performance tests; GS: grip strength; MMSE: mini mental state examination; GDS-15: 15 items geriatric
depression scale.
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(“Yes, without difficulty") with the total score of 6–30.
The relevant decline was determined using the Edwards-
Nunnally index that determines the probability of sub-
stantial individual change and avoids the problem of
regression to the mean [32]. This index computes
whether a significant change has occurred between T0and T1 based on the reliability of the scale and the 95%
Confidence Interval (CI) of the score at T0.
The PPT consisted of measured times of walking 3
meters and return, sitting and standing from a chair,
putting on and taking off a cardigan and maintaining
balance in a tandem stand [33-35]. For the first three
tasks, those who could not complete the task were
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scored 1–4 depending on the quartile of time needed to
complete the task (fastest time scored as 4). For the balance
in tandem stand, those who could not perform it or main-
tained the balance for less than 3 seconds were assigned a
score of 0, while those maintaining it until ≤9 seconds or
more were scored 1 and 2 respectively. The summary
performance score (range 0–14) was calculated by add-
ing up the category scores and ranked into gender-
specific quintiles. The relevant decline was defined as a
drop by at least two gender-specific quintiles in total
score between T0 and T1.
The grip strength was measured in the dominant hand
using a JAMAR® Plus digital handheld dynamometer
[36,37]. Three attempts at maximal squeeze were re-
corded. The relevant decline was defined as a drop by at
least two gender-specific quintiles of the best attempt
between T0 and T1.
Mental decline
The mini-mental state examination (MMSE) and the 15-
item Geriatric Depression Scale (GDS-15) were used to
assess the cognitive and mood/affective components of
the mental status respectively. Mental decline was de-
fined as a relevant decline in any of these tests between
T0 and T1.
The MMSE evaluates cognitive efficiency by examin-
ing orientation in time and space; short and middle term
memory; calculation; comprehension and constructive
praxis with scores range from 0 to 30 points (optimal)
[38]. The relevant decline was determined using the
Edwards-Nunnally index [32].
The GDS-15 has been designed to screen for depres-
sion in the older adults and has been found to have good
accuracy in the very old adults [39,40]. Its scores range
from 0 (optimal) to 15. The relevant decline was deter-
mined as a shift of score from <5 to ≥5 [41].
Potential confounding variables
In addition to age and sex, other potential confounding
variables associated with PF and the study outcomes
[4,6,16] were included in the statistical analysis as follows:
smoking status (never, previous or current smoker), high
sensitivity C-Reactive Protein (hs-CRP) > 0.3 mg/dl, serum
creatinine > 2 mg/dL, anemia (hemoglobin < 12 g/dL for
women and <13 g/dL for men), history of cardiovascular
disease (CVD), osteoporosis, Parkinson disease, diabetes,
hypertension as well as chronic respiratory morbidities
such as chronic obstructive pulmonary disease (COPD)
and asthma. The GP reported the recorded status of
smoking and the presence of morbidities at T0.
Plasma (EDTA) and serum samples were stored and
frozen in −8°C until analysis. Creatinine and hs-CRP were
measured in serum using the UniCel DxC 800 Synchron(Beckman-Coulter, Brea, USA). Hemoglobin was mea-
sured on whole blood using the Sysmex XE-2100 auto-
mated hematology analyzer (Milton Keynes, UK).
Statistical analysis
Descriptive statistics were calculated for baseline and
outcome variables. Continuous variables are presented
as mean ± standard deviation (SD) or median and inter-
quartile range (IQR), while categorical ones are pre-
sented as numbers and frequencies. FEV1/Ht
3 values
were ranked into two groups based on the quartiles of
their distribution: those in the lowest quartile and the
rest of the study population. Comparison of baseline and
outcome variables across the FEV1/Ht
3 quartiles was
tested using one way analysis of variance for parametric
variables, Kruskall-Wallis test for non-parametric vari-
ables and Pearson's Chi-Square test for categorical vari-
ables. Kaplan-Meier curves for all-cause mortality and
hospitalization during 3 years follow-up for the lowest
FEV1/Ht
3 quartile and the rest of the population were
compared using a log-rank test. Cox proportional hazards
regression model was used to estimate the hazard ratio
(HR) for mortality and hospitalization for the lowest
FEV1/Ht
3 quartile adjusting for potential confounders in
three consecutive models. Logistic regression model (ad-
justed for the abovementioned confounders in three con-
secutive models) was used to estimate the odds ratios
(OR) of the lowest FEV1/Ht
3 quartile for decline in phys-
ical and mental functioning. The rest of the study popula-
tion was used as reference category. Variables were first
checked for multicollinearity. A two-tailed probability
value p < 0.05 was considered statistically significant.
Statistical analysis was performed using SPSS 22.0 for
Windows (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of the study population
The BFc80+ cohort consisted of 567 participants and 522
of them performed spirometry during the CRA visit at
T0. The quality of spirograms was scored as ATS 1 in
226 participants (43.3%), ATS 2 in 214 (41%), ATS 3 in
61 (11.7%) and ATS 4 in 21 (4%). Participants with spir-
ograms scored as ATS 1–3 (501) were included in the
study population for our analysis (Figure 1). They were
comparable to the initial BFc80+ population with a mean
age of 84.79 (SD 3.66) and 186 (37.1%) men. The main
baseline demographic and clinical characteristics of the
study population in total and by FEV1/Ht
3 quartiles are
shown in Table 1. The differences in age and gender
across the FEV1/Ht
3 quartiles were statistically signifi-
cant with more female and older participants in the low-
est FEV1/Ht
3 quartile. Current or previous smoking was
present in 31.6% of the population with no statistically
significant differences in smoking status between the
Table 1 Baseline characteristics of the study population in total and across the FEV1/Ht
3 quartiles
Total population
(n = 501)
Lowest quartile
(n = 129)
Second quartile
(n = 111)
Third quartile
(n = 135)
Highest quartile
(n = 126)
p value
Age (years), mean ± SD 84.8 ± 3.7 85.6 ± 3.8 85.3 ± 3.8 84.7 ± 3.7 83.6 ± 3.0 0.00a
Male, n (%) 186 (37.1) 30 (23.3) 34 (29.6) 51 (38.1) 69 (54.8) 0.00b
BMI (kg/m2), mean ± SD 27.4 ± 4.9 26.7 ± 5.4 27.7 ± 4.9 28.1 ± 5.3 27.0 ± 3.7 0.11a
FEV1/Ht
3, mean ± SD 0.4 ± 0.1 0.3 ± 0.1 0.4 ± 0.0 0.4 ± 0.0 0.6 ± 0.1 0.00a
FEV1, mean ± SD 1.7 ± 0.6 1.1 ± 0.3 1.5 ± 0.3 1.8 ± 0.3 2.4 ± 0.5 0.00
a
Smoker/ex-smoker, n (%) 158 (31.6) 41 (32) 34 (29.6) 35 (26.1) 46 (36.5) 0.24b
COPD, n (%) 54 (10.8) 30 (23.4) 11 (9.6) 4 [17] 8 (6.3) 0.00b
Asthma, n (%) 24 (4.8) 12 (9.4) 5 (4.3) 5 (3.7) 2 (1.6) 0.03b
CVD history, n (%) 256 (51.1) 77 (60.2) 69 (60) 71 (53) 58 (46) 0.08b
Hypertension, n (%) 356 (71.2) 97 (75.8) 87 (75.7) 86 (64.2) 87 (69.1) 0.13b
Diabetes, n (%) 95 (19) 23 (18) 25 (21.7) 31 (23.1) 16 (12.7) 0.22b
Parkinson, n (%) 9 (1.8) 2 (1.6) 0 (0) 4 [17] 3 (2.4) 0.34b
Osteoporosis, n (%) 107 (21.7) 40 (31.7) 32 (28.6) 23 (17.3) 15 (12.1) 0.00b
Anemia, n (%) 99 (20) 25 (19.7) 25 (21.7) 23 (17.4) 27 (21.8) 0.90b
hs-CRP (mg/dl), median [IQR] 0.18 [0.1-0.4] 0.22 [0.1-0.6] 0.17 [0.1-0.4] 0.15 [0.1-0.3] 0.15 [0.1-0.4] 0.02c
Serum creatinine (mg/dl), median [IQR] 0.95 [0.8-1.2] 0.92 [0.7-1.2] 0.93 [0.8-1.1] 0.90 [0.8-1.2] 1.0 [0.8-1.2] 0.17c
ADL score at T0, median [IQR] 25 [21–27] 22 [17.3-26] 25 [21–27] 25 [22–28] 27 [24–29] 0.00
c
PPT score at T0, median [IQR] 9 [5–11] 7 [4–9] 8 [5–11] 8 [6–11] 10 [7–12] 0.00
c
Grip strength at T0, median [IQR] 20 [15.1-26.3] 16.9 [12.7-21.3] 18.7 [14.8-23] 20.2 [15.5-26.2] 25.3 [19.4-33.9] 0.00
c
MMSE score at T0, median [IQR] 28 [26–29] 27 [24.3-29] 28 [26–29] 28 [25.3-29] 28 [27–30] 0.00
c
GDS-15 score at T0, median [IQR] 2 [1–4] 2 [2–5] 3 [1–4.3] 2 [1–3] 2 [1–3] 0.00
c
BMI: body mass index; FEV1/Ht
3: forced expiratory volume in one second over height cubed; COPD: chronic obstructive pulmonary diseases; CVD: cardiovascular
disease; hs-CRP: high sensitivity C-reactive protein; ADL: activities of daily living; T0: baseline assessment; PPT: physical performance tests; MMSE: mini-mental state
examination; GDS: geriatric depression scale; abased on one way ANOVA; bbased on Pearson Chi-Square; cbased on Kruskall-Wallis.
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3 quartiles. All of the components of physical
and mental functioning at baseline (ADL, PPT, grip
strength, MMSE and GDS-15) showed a statistically sig-
nificant difference across the FEV1/Ht
3 quartiles with
worse scores in the lowest FEV1/Ht
3 quartile. The preva-
lence of asthma and COPD in the study population was
4.8% and 10.8% respectively. The differences in prevalence
of asthma, COPD and osteoporosis across the FEV1/Ht
3
quartiles were statistically significant with higher preva-
lence in the lowest quartile.All-cause mortality and hospitalization
Follow-up data for mortality were available for all the
participants (501), while data on hospitalizations were
available for 494 of them. During the 3.0 ± 0.25 years of
follow up, 115 (23%) participants died and 249 (50.4%)
had at least one hospitalization reported. Kaplan-Meier
survival curves showed significant higher all-cause mor-
tality and hospitalization at 3 years follow up for the par-
ticipants in the lowest FEV1/Ht
3 quartile (Figure 2).
Even after adjustment for the potential confounders inthe Cox proportional hazards model, participants with
FEV1/Ht
3 in the lowest quartile had a higher risk of all-
cause mortality and hospitalizations with adjusted HR of
1.69 (95% CI 1.10-2.60, p < 0.05) and 1.65 (95% CI 1.21-
2.25, p < 0.01) respectively (Table 2).Physical and mental decline
Complete data regarding physical and mental decline
after 1.7 ± 0.21 years follow-up were available for 378
participants. As defined for the purposes of this analysis,
physical and mental decline were identified respectively
in 116 (30.7%) and 85 (22.5%) participants. The associ-
ation between the lowest quartile of FEV1/Ht
3 and phys-
ical decline was not statistically significant in unadjusted
analysis. After adjustment for anemia, high CRP and cre-
atinine, a significant positive association was found be-
tween the lowest FEV1/Ht
3 quartile and physical decline
with OR 1.89 (95%CI 1.05-3.39 p < 0.05). Participants in
the lowest FEV1/Ht
3 quartile had a statistically signifi-
cant increased risk for mental decline with adjusted OR
of 2.39 (95% CI 1.30-4.40 p < 0.01) (Table 3).
Number at risk 
Rest of population   
Lowest quartile    
Number at risk 
Rest of population   
Lowest quartile    
372 357 330 68
129 116 99 29
368 304 236 43
117 78 55 15
Figure 2 Kaplan-Meier survival curves for 3 years all-cause mortality and hospitalization for the lowest quartile of FEV1/Ht
3 and rest of
study population.
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Main findings and comparison with previous research
In a population-based prospective cohort of very old
adults, we found that low FEV1 expressed as FEV1/Ht
3
was associated with all-cause mortality, unplanned
hospitalization as well as decline in mental and physical
functioning independent of multiple potential con-
founders including age, smoking, chronic lung disease
and an inflammation marker.
In previous clinical population studies including older
adults, FEV1/Ht
3 has been found to be better than
FEV1% for predicting all-cause mortality, but it has not
yet been investigated in relation to other adverse health
outcomes [23,25,26]. Our study found the lowest quar-
tile of FEV1/Ht
3 to be associated with all-cause mortality
in 3 years follow up of a cohort of very old adults who
have not been the primary focus of previous studies.
This association remained even after adjustment for a
variety of potential confounders such as respiratory and
non-respiratory co-morbidities, high levels of hs-CRP
and serum creatinine that were not used in previous
studies. In addition, our study explored the association
of FEV1/Ht
3 with other adverse outcomes such as un-
planned hospitalizations and decline in physical and
mental functioning that are particularly relevant for the
very old adults.
In our cohort, those in the lowest FEV1/Ht
3 quartile
had a significantly higher risk for unplanned hospitalization
during the 3 year follow-up, even after adjustment formultiple potential confounders. We also found that being
in the lowest quartile of FEV1/Ht
3 more than doubled the
risk for mental decline (as defined for the purposes of our
analysis) at 1.7 ± 0.21 years follow-up. Previous studies
have found lower FEV1 (including different height- adjust-
ments) to be associated with lower scores in cognitive tests
and higher risk for cognitive decline over long term
[7,12,13,15-17]. Our study investigated and confirmed for
the first time the predictive value of FEV1/Ht
3 for mental
decline in a cohort of very old adults using standardized
assessment of both cognitive and mood components.
Regarding physical decline, in line with previous studies
where lower PF has been found to be associated with poor
physical functioning [7-10,42], we found a significant asso-
ciation at baseline between FEV1/Ht
3 and each of the
physical functioning components used in our study (ADL
score, PPT score and grip strength). Our study explored
for the first time the association of FEV1 expressed as
FEV1/Ht
3 and decline in physical functioning over 1.7 ±
0.21 years follow-up in a cohort of very old adults using
both self-reporting (ADL) and performance-based tests
(PPT and grip strength). We found that the lowest quartile
of FEV1/Ht
3 had a statistically significant higher risk for
physical decline only after adjustment for multiple con-
founders. These findings show a trend for a positive asso-
ciation of lowered FEV1/Ht
3 with physical decline. Further
investigations are needed to explore this association using
longer follow-up time as well as other definitions and
cut-offs for physical decline and its components.
Table 2 Multivariable Cox regression analysis for all-cause mortality and hospitalization
Mortality (N = 478) Hospitalization (N = 463)
Hazard ratio (95% confidence interval)
Variables Unadjusted model Model 1 Model 2 Model 3 Unadjusted model Model 1 Model 2 Model 3
Lowest FEV1/Ht
3 quartile 2.13 (1.46-3.09)** 2.13 (1.44-3.14)** 1.77 (1.16-2.70)** 1.69 (1.10-2.60)* 1.68 (1.27-2.21)** 1.73 (1.30-2.31)** 1.56 (1.15-2.11)** 1.65 (1.21-2.25)**
Age 1.08 (1.03-1.13)** 1.07 (1.02-1.12)** 1.06 (1.01-1.11)* 1.04 (1.01-1.08)* 1.04 (1.00-1.07) 1.02 (0.99-1.06)
Male 1.44 (0.98-2.11) 1.08 (0.64-1.81) 0.91 (0.53-1.57) 1.42 (1.09-1.85)* 1.19 (0.82-1.74) 0.99 (0.67-1.47)
Smoker or ex-smoker 1.34 (0.81-2.21) 1.41 (0.86-2.34) 1.40 (0.98-2.00) 1.50 (1.04-2.14)*
History of CVD 1.48 (0.99-2.21) 1.45 (0.96-2.18) 1.46 (1.11-1.91)** 1.37 (1.04-1.82)*
Hypertension 1.61 (1.01-2.55)* 1.53 (0.95-2.48) 1.25 (0.92-1.68) 1.25 (0.92-1.70)
Diabetes 0.72 (0.42-1.21) 0.68 (0.40-1.15) 1.19 (0.86-1.65) 1.09 (0.78-1.52)
Parkinson disease 1.43 (0.35-5.94) 1.76 (0.42-7.35) 0.69 (0.21-2.20) 0.91 (0.28-2.94)
Osteoporosis 1.18 (0.74-1.86) 1.24 (0.77-1.99) 1.51 (1.08-2.09)* 1.55 (1.10-2.17)*
Asthma 1.01 (0.43-2.37) 0.99 (0.42-2.33) 1.50 (0.85-2.65) 1.39 (0.78-2.49)
COPD 1.52 (0.87-2.68) 1.56 (0.87-2.78) 1.08 (0.70-1.65) 1.02 (0.65-1.59)
Anemia 1.53 (0.98-2.38) 1.56 (1.14-2.15)**
hs-CRP > 0.3 mg/dl 1.37 (0.93-2.03) 1.27 (0.96-1.67)
Serum creatinine > 2 mg/dl 1.53 (0.72-3.26) 2.30 (1.32-4.03)**
FEV1/Ht
3: Forced expiratory volume in one second divided by height cubed; CVD: cardiovascular disease; COPD: chronic obstructive pulmonary diseases; hs-CRP: high sensitivity C-Reactive Protein; Model 1: adjusted for
age and sex; Model 2: Model 1+ smoking status and other co-morbidities reported by GP; Model 3: Model 2+ anemia, hs-CRP and serum creatinine; *p-value < 0.05 **p-value < 0.01.
Turkeshiet
al.BM
C
G
eriatrics
 (2015) 15:15 
Page
7
of
10
Table 3 Multivariable logistic regression analysis for physical and mental decline
Physical decline (N = 362) Mental decline (N = 362)
Odds ratio (95% Confidence interval)
Predictor variables Unadjusted model Model 1 Model 2 Model 3 Unadjusted model Model 1 Model 2 Model 3
Lowest FEV1/Ht
3 quartile 1.54 (0.93-2.56) 1.45 (0.86-2.46) 1.70 (0.96-3.01) 1.89 (1.05-3.39)* 2.54 (1.49-4.32)** 2.36 (1.37-4.06)** 2.39 (1.32-4.33)** 2.39 (1.30-4.40)**
Age 1.11 (1.04-1.18)** 1.11 (1.04-1.19)** 1.10 (1.03-1.18)** 1.11 (1.04-1.19)** 1.10 (1.02-1.18)** 1.08 (1.00-1.17)*
Male 1.06 (0.66-1.70) 0.94 (0.49-1.79) 0.95 (0.49-1.90) 0.90 (0.53-1.54) 0.71 (0.34-1.48) 0.70 (0.32-1.50)
Smoker or ex-smoker 1.15 (0.60-2.20) 0.96 (0.49-1.90) 1.55 (0.75-3.21) 1.68 (0.79-3.56)
History of CVD 1.13 (0.70-1.83) 1.09 (0.67-1.80) 1.17 (0.68-2.00) 1.18 (0.68-2.06)
Hypertension 1.16 (0.69-1.96) 1.15 (0.66-1.98) 1.44 (0.80-2.62) 1.49 (0.80-2.78)
Diabetes 0.69 (0.37-1.29) 0.63 (0.33-1.19) 0.38 (0.17-0.84)* 0.40 (0.18-0.87)*
Parkinson disease 4.00 (0.56-28.46) 2.38 (0.27-21.45) 3.65 (0.47-28.42) 1.46 (0.10-20.41)
Osteoporosis 0.62 (0.33-1.16) 0.62 (0.33-1.17) 0.93 (0.48-1.82) 0.90 (0.45-1.79)
Asthma 2.41 (0.80-7.24) 2.63 (0.88-7.88) 1.01 (0.25-4.05) 1.09 (0.27-4.40)
COPD 0.44 (0.16-1.20) 0.47 (0.17-1.29) 0.52 (0.18-1.50) 0.50 (0.17-1.47)
Anemia 1.65 (0.89-3.04) 0.94 (0.46-1.91)
hs-CRP > 0.3 mg/dl 1.26 (0.76-2.08) 0.87 (0.49-1.54)
Serum creatinine >2 mg/dl 1.23 (0.37-4.08) 1.83 (0.53-6.32)
FEV1/Ht
3: Forced expiratory volume in one second divided by height cubed; CVD: cardiovascular disease; COPD: chronic obstructive pulmonary diseases; hs-CRP: high sensitivity C-Reactive Protein; Model 1: adjusted for
age and sex; Model 2: Model 1+ smoking status and other co-morbidities reported by GP; Model 3: Model 2+ anemia, hs-CRP and serum creatinine; *p-value < 0.05 **p-value < 0.01.
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rameters of PF with adverse health in the older adults
have used different standardizations of FEV1 and mea-
sures of physical and mental functioning and have also
not focused on the growing population of very old
adults. More longitudinal studies are needed in this area,
especially as the association of spirometry-based respira-
tory impairment with frailty as well as their combined
effect on mortality has been recently hypothesized and
tested in adults 65–80 years old supporting the explor-
ation of PF parameters as prognostic markers of frailty
and adverse health outcomes in the older adults [18].
This is of interest as frailty is prevalent in the older
adults and a precursor of disability and other adverse
outcomes, but may be reversible in its early stages
[43-45]. Yet, there is no consensus on the best instru-
ment for assessment of frailty and in light of its multi-
domain phenotype current focus is on cognitive, mood
and social components beside the classical physical ones
[46]. Our findings support the need for further research
on the use of FEV1 as a predictor for important adverse
outcomes and potential frailty marker in the very old
adults and consideration as an indicator of overall health
in geriatric assessments [1,7]. FEV1 standardized as FEV1/
Ht3 takes into account the variability of body size and
does not require the use of reference values and equations
so it may be more suitable for use in this age group.
Strengths and limitations
This study has several strengths. It is based on a large
heterogeneous population representative of the very old
adults in Belgium [28]. The protocol of the BFc80+ study
included a comprehensive geriatric assessment that
allowed for a rich analysis of different outcomes and risk
factors. The same standardized examination and ques-
tionnaires were applied to all participants as the involved
GPs and CRAs received training in order to standardize
the data collection and recording. Mental and physical
functioning was assessed with standardized and validated
self-reported and performance-based tests. Rigorous
quality control of spirometry performance and interpret-
ation based on the ATS/ERS quality criteria were
followed and various confounders were included in the
analysis covering demographics, smoking status, non-
respiratory and respiratory co-morbidities as well as a
marker of systemic inflammation (hs-CRP).
The exclusion criteria in the selection of participants
for the BFc80+ study (dementia or severe cognitive im-
pairment and being in palliative or emergency care) are
one of the limitations of this study. The definitions of
physical and mental decline in our study were not based
on a validated scoring method and the cut-off values for
decline in some of the components may have missed or
overestimated some of the change. We also used theactual instead of true height in our study. This becomes
an issue in the older adults as height reduction is fre-
quent in this age group due to both ageing and disease-
related osteoporotic vertebral changes and introduces
bias in lung function testing with possible overestimation
of its values [26]. While the effect of height reduction has
been found to be smallest on FEV1 and FVC, other prox-
ies of height could be considered such as recalled tallest
height or height calculated on arm span [47]. We plan to
explore this in future studies as arm span has been mea-
sured in the BFc80+ study population.
Conclusions
In a representative sample of adults 80 years and older, a
low FEV1/Ht
3 was an independent short-term predictor
of all-cause mortality and hospitalizations as well as de-
cline in physical and mental functioning. These findings
support the consideration of FEV1/Ht
3 as an alternative
way of standardizing FEV1 and further exploration of its
role as a potential risk marker for frailty and adverse
health outcomes in very old adults.
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